Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
Type:
Grant
Filed:
November 2, 2012
Date of Patent:
March 11, 2014
Assignees:
Tokyo Metropolitan Institute of Medical Science, Altif Laboratories
Abstract: The present invention provides a pharmaceutical composition comprising a protein having ?-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an ?-galactosidase activity through alteration of the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
Type:
Grant
Filed:
May 19, 2008
Date of Patent:
October 29, 2013
Assignees:
Tokyo Metropolitan Institute of Medical Science, ALTIF Laboratories Inc.
Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
Type:
Grant
Filed:
March 21, 2011
Date of Patent:
December 4, 2012
Assignees:
Tokyo Metropolitan Organization For Medical Research, Altif Laboratories
Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
Type:
Grant
Filed:
November 17, 2006
Date of Patent:
May 3, 2011
Assignees:
Tokyo Metropolitan Organization for Medical Research, ALTIF Laboratories
© 2025 Justia
